If you have been reading about alpha-MSH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-18. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
== See also == Ghulam Ishaq Khan Institute of Engineering Sciences and Technology University of Swabi Women University Mardan Shaheed Benazir Bhutto Women University, Peshawar Government Post Graduate College (Swabi)
The enzyme cystathionine γ-lyase (EC 4.4.1.1, CTH or CSE; also cystathionase; systematic name L-cystathionine cysteine-lyase (deaminating; 2-oxobutanoate-forming)) is an enzyme which in humans is encoded by the gene CTH. CTH enzymes break down cystathionine into cysteine, 2-oxobutanoate (α-ketobutyrate), and ammonia:
== Critical reception == The mod was well received by critics and fans alike. Matthew Byrd of Den of Geek called the mod "something that Half-Life fans should consider playing." For the week of August 18, 2018, it was one of the biggest stories on Mod DB. Liana Ruppert of Comicbook.com said that Echoes had "the compelling storyline, the intrigue - Echoes has it all!" Rick Lane of Bit-Tech called it "a superb, expansion-quality mod, and a must-play for any Half-Life fan." Half-Life: Echoes placed 3rd for the 2018 Mod of the Year Players' Choice and was an honorable mention for the 2019 Mod of the Year.
Sources: en.wikipedia.org
== Behaviour and ecology == Emus are diurnal birds and spend their day foraging, preening their plumage with their beak, dust bathing and resting. They are generally gregarious birds apart from the breeding season, and while some forage, others remain vigilant to their mutual benefit. They are able to swim when necessary, although they rarely do so unless the area is flooded or they need to cross a river.
=== Critiques and Limitations of the Agreement === The Algiers Peace Accords have been subject to substantial criticism from various stakeholders, including the Malian government, CMA, and international observers. One major critique centres on the lack of inclusivity in the agreement. The accord primarily focused on the interests of armed groups involved in the conflict, neglecting the concerns of sedentary populations. This exclusion has led to ongoing resentment and contributed to the formation of new militia groups, which further destabilised northern Mali. Another significant critique is that the accord inadvertently rewarded rebellion. By offering political and military concessions to groups that had taken up arms against the state, the peace process was seen by many in Mali as a capitulation. This perception fuelled the belief that future uprisings could extract similar concessions from the government. Additionally, the agreement's failure to address key economic drivers of the conflict, such as drug and arms trafficking, has been a notable shortcoming. Some signatories to the accord have been accused of continuing to engage in illicit trade, which undermines the peace process and fosters further instability.
On 18 June 2025, a 9-minute excerpt of the call between Paetongtarn Shinawatra and Hun Sen was leaked. Hun Sen responded by admitting that he had recorded the 15 June call and distributed the recording to around 80 Cambodian officials. Later on 18 June, Hun Sen published on Facebook the entire 17-minute call "to avoid any misunderstanding or misrepresentation". Paetongtarn acknowledged on the same day that it was her speaking in the leaked call. The call recording showed Paetongtarn addressing Hun Sen as "uncle" and referring to herself as his "niece". Urging him to ignore "our opponents", Paetongtarn cited "the commander of the Second Army Region", Thai general Boonsin Padklang, as "a man of the opponents", who "wanted to look smart", and "said what was not beneficial to the nation" (Boonsin had declared that Thailand was "ready to fight"); instead Paetongtarn asserted: "we want the peace that happened before the clash at the border". Paetongtarn commented that she did not publicly react to Hun Sen's hostile Facebook posts regarding the border because she "loves and respects" Hun Sen. Paetongtarn further said that if Hun Sen "wants anything, he can just tell me, and I will take care of it". Her comments were widely perceived by the Thai public and political opponents as weak, inexperienced, and compromising to national dignity and the morale of the armed forces. Paetongtarn also expressed frustration over domestic political pressure and criticism concerning her handling of the border crisis.
=== Stannane === Organostannane reagents are common. Several are commercially available. Stannane reagents can be synthesized by the reaction of a Grignard or organolithium reagent with trialkyltin chlorides. For example, vinyltributyltin is prepared by the reaction of vinylmagnesium bromide with tributyltin chloride. Hydrostannylation of alkynes or alkenes provides many derivatives. Organotin reagents are air and moisture stable. Some reactions can even take place in water. They can be purified by chromatography. They are tolerant to most functional groups. Some organotin compounds are heavily toxic, especially trimethylstannyl derivatives. The use of vinylstannane, or alkenylstannane reagents is widespread. In regards to limitations, both very bulky stannane reagents and stannanes with substitution on the α-carbon tend to react sluggishly or require optimization. For example, in the case below, the α-substituted vinylstannane only reacts with a terminal iodide due to steric hindrance.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.